These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23343800)

  • 1. Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy.
    Renet S; Closon A; Brochet MS; Bussières JF; Boucher M
    J Obstet Gynaecol Can; 2013 Jan; 35(1):68-72. PubMed ID: 23343800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.
    Nóbrega I; Travassos AG; Haguihara T; Amorim F; Brites C
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1451-4. PubMed ID: 23731224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report.
    Cha A; Shaikh R; Williams S; Berkowitz LL
    J Int Assoc Provid AIDS Care; 2013; 12(5):312-4. PubMed ID: 23695227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
    Brites C; Nóbrega I; Luz E; Travassos AG; Lorenzo C; Netto EM
    HIV Clin Trials; 2018 Jun; 19(3):94-100. PubMed ID: 29629852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
    De Hoffer L; Di Biagio A; Bruzzone B; Sticchi L; Prinapori R; Gerbaldo D; Gotta C; Viscoli C
    J Chemother; 2013 Jun; 25(3):181-3. PubMed ID: 23783144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An HIV-infected Pregnant Woman Treated with the Long-term Administration of Antiretroviral Therapy Including Raltegravir.
    Yaita K; Inoue S; Horinouchi T; Kinoshita M; Unno M; Iwata O; Tanaka Y; Gotoh K; Ishibashi M; Sakai Y; Masunaga K; Watanabe H; Tominaga M
    Intern Med; 2016; 55(18):2727-30. PubMed ID: 27629976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
    Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
    Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
    Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S
    Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
    Croce F; Vitello P; Dalla Pria A; Riva A; Galli M; Antinori S
    Int J STD AIDS; 2010 Nov; 21(11):783-5. PubMed ID: 21187364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral load in HCV RNA-positive pregnant women.
    Paternoster DM; Santarossa C; Grella P; Palù G; Baldo V; Boccagni P; Floreani A
    Am J Gastroenterol; 2001 Sep; 96(9):2751-4. PubMed ID: 11569706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
    HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C.
    Cevik M; Katsarolis I; Singh GJ; Nelson M
    J Infect; 2014 Aug; 69(2):190-3. PubMed ID: 24793307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission.
    Hegazi A; Hay P
    Int J STD AIDS; 2013 Mar; 24(3):245-6. PubMed ID: 23440569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
    Yee BE; Nguyen NH; Lee D
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24798353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.